Topic: Next Gen Sequencing

Clinical Genome Data Analysis Workshop in China

To educate the community and encourage sharing of experiences and knowledge within the genetic testing labs, Be Creative recently hosted a workshop on clinical data analysis and interpretation using NxClinical.

Did you catch the PerkinElmer Genomics' webinar on their new CNGnome test using NxClinical for analysis & interpretation?

Using a combination of genomic sequencing technologies and bioinformatic tools, PerkinElmer Genomics is paving the way to replace traditional microarray analyses for constitutional genomics with NGS. Dr. Alka Chaubey, PerkinElmer Genomics, presented development and validation of the new CNGnome™ Test and comparison to traditional CMA. Dr. Chaubey also discusses how NxClinical was selected for use with their new assay and shows how the software was invaluable in the interpretation process.

Significant Cost Savings with Single NGS Test vs. Other Strategies

At the American Society of Clinical Oncology (ASCO) meeting last month, Dr. Nathan Pennell, Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic, and his colleagues presented cost analysis in a model with different types of genetics testing in metastatic non-small cell lung cancer (mNSCLC). The team showed that upfront NGS leads to significant cost savings vs. sequential single-gene testing modalities.

The Secret is out - NxClinical 4.1 is here!

We are excited to announce the release of NxClinical 4.1! Our unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.

Happy 2018 - the year of the single NGS assay approach

Happy 2018! 2017 saw a renewed interest in copy number analysis particularly from NGS data and I think it's going to be a key topic in 2018. The ability to obtain copy number from the same assay as that used for SNVs is an important topic among genetics labs. Clinicians are now starting to realize the major benefits in consolidating tests to a single NGS assay analyzed on a single software system.

Back from China with a Partnership with Be Creative

BioDiscovery inked a deal with Be Creative Lab (Beijing) Co. Ltd. where Be Creative will be the sole reseller and distributor of BioDiscovery products in China. Be Creative is a clinical genetic testing center in Beijing, China, providing diagnostic support for a number of hospitals. Be Creative debuted NxClinical 4.0 at the Clinical Applications Conference which focused on comprehensive application of SNP-Array, NGS and other technology platforms to enhance clinical diagnostics. The conference, hosted by Be Creative, brought together 200 clinical genetics experts.

As NFL season starts, BioDiscovery kicks off with upcoming new software releases

BioDiscovery is starting its new season with new product releases at ASHG in mid-October. It is bound to bring excitement to the genetic testing field, as NFL does to the football fans. Since NGS (next-generation sequencing) is still a hot topic, people will see lots of new things on this front in BioDiscovery's NxClinical 4.0 version.

Recent advances in research: Next generation sequencing of mitochondrial mummy DNA

A recent article in Nature Communications describes the use of mitochondrial DNA sequencing to study population genomics in ancient civilizations. Mitochondrial DNA from a set of 151 ancient Egyptian mummies from a 1300 year span were sequenced.

Nexus Copy Number 9.0 is here

Nexus Copy Number 9.0 is coming this month! It contains a new method that is called BAM (multiscale reference). It derives copy number results from whole genome sequencing (WGS), whole exome sequencing (WES), and targeted panel sequencing data.

Can I Get Quality Copy Number Results from NGS data?

We have come a long way in a short amount of time with NGS (next-generation sequencing) technologies. Learn more about the benefits here!